New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well ...

Monthly oral PrEP pill advances to phase III trials Professor Kenneth Mayer at IAS 2025. ©Jacques Nkinzingabo/IAS. CC BY-SA 4.0. A once-monthly oral HIV prevention pill has shown promising results in ...

Intermittent HIV treatment schedules – such as weekends off treatment – may not be inferior to continuous treatment in adults with well-controlled HIV, but they are not suitable for adolescents with ...

Injectable treatment with long-acting cabotegravir and rilpivirine is as effective as dolutegravir-based oral treatment in adults with HIV in sub-Saharan Africa who have a history of treatment ...

The 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda has been dominated by the impact of the US government funding cuts. Especially urgent are discussions on ...

A randomised trial presented on Tuesday at the 13th International AIDS Society Conference on HIV Science (IAS 2025) showed that switching from medications thought to cause weight gain did ...

An investigational once-monthly pill holds promise for HIV pre-exposure prophylaxis (PrEP), according to mid-stage study results presented yesterday at the 13th International AIDS Society Conference ...

One year ago, UNAIDS announced that the HIV response was at a critical crossroads. Apart from a handful of countries, the world was not on track to meet the ambitious 2030 goals: 95% of those ...

As doxycycline post-exposure prophylaxis (doxyPEP) for prevention of sexually transmitted infections (STIs) enters widespread use, questions remain about its implementation in the real world. At a ...

Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective ...

Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco last week found that so far relatively few people with HIV are taking ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...